NCT01342250

Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis

Phase Ι/Π Study of Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Shenzhen Beike Bio-Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Although liver transplantation provide a option to cure patients suffering with decompensated liver cirrhosis this condition, lack of donors, postoperative complications, especially rejection, and high cost limit its application. Bone marrow derived mesenchymal stem cells (BM-MSCs) have been shown to replace hepatocytes in injured liver, effectively rescued experimental liver failure and contributed to liver regeneration, which suggest the novel and promising therapeutic strategy In this study, the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSCs) transplantation for patients with decompensated liver cirrhosis will be evaluated.

Detailed description

To investigate the safety and efficacy of human umbilical cord mesenchymal stem cells transplantation in patients of decompensated liver cirrhosis.

Conditions

• Liver Cirrhosis

Interventions

Type	Name	Description
BIOLOGICAL	conventional therapy plus low dose hUC-MSCs treatment	patients will receive the conventional therapy plus low dose hUC-MSCs treatment
BIOLOGICAL	conventional therapy plus medium dose hUC-MSCs treatment	patients will receive conventional therapy plus medium dose hUC-MSCs treatment
BIOLOGICAL	conventional therapy plus high dose hUC-MSCs treatment	patients will receive conventional therapy plus high dose hUC-MSCs treatment

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-07-01
• Completion: 2011-10-01
• First posted: 2011-04-27
• Last updated: 2011-10-14

Locations

1 site across 1 country: China